Single case of a complete response in a metastatic urothelial carcinoma patient treated with zoptarelin doxorubicin

Gustavo Fernandez, Andrew V Schally, Tulay Sengul, Merce Jorda, Jaime R Merchan, Aurea M. Flores, Maria H Restrepo, Norman L Block

Research output: Contribution to journalArticle

Abstract

Background: Zoptarelin doxorubicin (AEZS-108, AN-152) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was diagnosed in May 2009 with metastatic urothelial carcinoma (UC) of the prostatic urethra. He presented with pelvic and retroperitoneal lymph nodes (LNs). Initially he was treated with cisplatin and gemzar, followed by radical cystoprostatectomy in October 2009. He relapsed in December 2009 and he received two more lines of chemotherapy with no response. The patient entered a phase I clinical trial with zoptarelin doxorubicin, in 2011. He received zoptarelin doxorubicin every 3 weeks for nine cycles from May to October 2011. Results: After two cycles of the investigational drug, all pain and palpable lymph neck nodes disappeared. A computed tomography (CT) scan 20 months post-treatment showed a complete response. Thirty months after treatment started, the patient is symptom free with no evidence of disease. Conclusions: This is the first case of a patient with LHRH-receptor (LHRH-R) positive UC treated with zoptarelin doxorubicin that has been reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable.

Original languageEnglish
JournalEuropean Oncology and Haematology
Volume10
Issue number2
StatePublished - Jan 1 2014

Fingerprint

Carcinoma
gemcitabine
Lymph Nodes
Investigational Drugs
LHRH Receptors
Clinical Trials, Phase I
Urethra
Gonadotropin-Releasing Hormone
Pharmaceutical Preparations
Doxorubicin
Cisplatin
lysine(6)-doxorubicin LHRH
Neck
Tomography
Drug Therapy
Pain
Survival
Therapeutics

Keywords

  • AEZS-108
  • LHRH
  • Relapse
  • Targeted
  • Urothelial carcinoma
  • Zoptarelin doxorubicin

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{e70abfe34c5446219af64c9e7afb0356,
title = "Single case of a complete response in a metastatic urothelial carcinoma patient treated with zoptarelin doxorubicin",
abstract = "Background: Zoptarelin doxorubicin (AEZS-108, AN-152) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was diagnosed in May 2009 with metastatic urothelial carcinoma (UC) of the prostatic urethra. He presented with pelvic and retroperitoneal lymph nodes (LNs). Initially he was treated with cisplatin and gemzar, followed by radical cystoprostatectomy in October 2009. He relapsed in December 2009 and he received two more lines of chemotherapy with no response. The patient entered a phase I clinical trial with zoptarelin doxorubicin, in 2011. He received zoptarelin doxorubicin every 3 weeks for nine cycles from May to October 2011. Results: After two cycles of the investigational drug, all pain and palpable lymph neck nodes disappeared. A computed tomography (CT) scan 20 months post-treatment showed a complete response. Thirty months after treatment started, the patient is symptom free with no evidence of disease. Conclusions: This is the first case of a patient with LHRH-receptor (LHRH-R) positive UC treated with zoptarelin doxorubicin that has been reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable.",
keywords = "AEZS-108, LHRH, Relapse, Targeted, Urothelial carcinoma, Zoptarelin doxorubicin",
author = "Gustavo Fernandez and Schally, {Andrew V} and Tulay Sengul and Merce Jorda and Merchan, {Jaime R} and Flores, {Aurea M.} and Restrepo, {Maria H} and Block, {Norman L}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "10",
journal = "European Oncology and Haematology",
issn = "2045-5275",
publisher = "Touch Digital Media",
number = "2",

}

TY - JOUR

T1 - Single case of a complete response in a metastatic urothelial carcinoma patient treated with zoptarelin doxorubicin

AU - Fernandez, Gustavo

AU - Schally, Andrew V

AU - Sengul, Tulay

AU - Jorda, Merce

AU - Merchan, Jaime R

AU - Flores, Aurea M.

AU - Restrepo, Maria H

AU - Block, Norman L

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Zoptarelin doxorubicin (AEZS-108, AN-152) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was diagnosed in May 2009 with metastatic urothelial carcinoma (UC) of the prostatic urethra. He presented with pelvic and retroperitoneal lymph nodes (LNs). Initially he was treated with cisplatin and gemzar, followed by radical cystoprostatectomy in October 2009. He relapsed in December 2009 and he received two more lines of chemotherapy with no response. The patient entered a phase I clinical trial with zoptarelin doxorubicin, in 2011. He received zoptarelin doxorubicin every 3 weeks for nine cycles from May to October 2011. Results: After two cycles of the investigational drug, all pain and palpable lymph neck nodes disappeared. A computed tomography (CT) scan 20 months post-treatment showed a complete response. Thirty months after treatment started, the patient is symptom free with no evidence of disease. Conclusions: This is the first case of a patient with LHRH-receptor (LHRH-R) positive UC treated with zoptarelin doxorubicin that has been reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable.

AB - Background: Zoptarelin doxorubicin (AEZS-108, AN-152) is an luteinising hormone-releasing hormone (LHRH)-cytotoxic hybrid drug consisting of an agonist coupled to the cytotoxic radical, doxorubicin. Methods: This is a single case report of a 66-year-old male who was diagnosed in May 2009 with metastatic urothelial carcinoma (UC) of the prostatic urethra. He presented with pelvic and retroperitoneal lymph nodes (LNs). Initially he was treated with cisplatin and gemzar, followed by radical cystoprostatectomy in October 2009. He relapsed in December 2009 and he received two more lines of chemotherapy with no response. The patient entered a phase I clinical trial with zoptarelin doxorubicin, in 2011. He received zoptarelin doxorubicin every 3 weeks for nine cycles from May to October 2011. Results: After two cycles of the investigational drug, all pain and palpable lymph neck nodes disappeared. A computed tomography (CT) scan 20 months post-treatment showed a complete response. Thirty months after treatment started, the patient is symptom free with no evidence of disease. Conclusions: This is the first case of a patient with LHRH-receptor (LHRH-R) positive UC treated with zoptarelin doxorubicin that has been reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable.

KW - AEZS-108

KW - LHRH

KW - Relapse

KW - Targeted

KW - Urothelial carcinoma

KW - Zoptarelin doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=84920982730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920982730&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84920982730

VL - 10

JO - European Oncology and Haematology

JF - European Oncology and Haematology

SN - 2045-5275

IS - 2

ER -